8-K: OmniAb Reports Full Year 2023 Results, Highlights Partner Progress and New Technology Launches

OmniAb reported its fourth quarter and full year 2023 financial results, noting a decrease in revenue due to a prior year milestone payment, but highlighted significant progress in partner programs and technology launches.

Summary

• OmniAb announced its financial results for the three and twelve months ended December 31, 2023.
• Fourth quarter revenue was $4.8 million, a decrease from $35.3 million in the same period of 2022, primarily due to a $25 million milestone payment in the prior year and lower service revenue.
• Full year 2023 revenue was $34.2 million, down from $59.1 million in 2022, mainly due to a decrease in TECVAYLI milestone payments from $25 million to $10 million.
• The company reported a net loss of $14.1 million for the fourth quarter of 2023, compared to a net income of $6.8 million in the same period of 2022.
• The net loss for the full year 2023 was $50.6 million, compared to a net loss of $22.3 million in 2022.
• Operating expenses are expected to be approximately the same in 2024 as in 2023.
• Cash use in 2024 is expected to be similar to 2023, excluding the $35 million TECVAYLI milestone payment received in 2023.
• The company expects cash use in 2025 to be substantially lower than in 2024 due to the progression of partnered programs.
• OmniAb had $87 million in cash, cash equivalents, and short-term investments as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While there are positive developments in partner programs and technology launches, the significant decrease in revenue and net loss are concerning. The company's future outlook is cautiously optimistic, but the financial results temper the overall sentiment.

Positives

• The company signed 10 new licenses in 2023, indicating strong business development.
• Six new OmniAb-derived antibodies entered the clinic, demonstrating the platform's effectiveness.
• The launch of OmniDeep and OmnidAb technologies enhances the company's capabilities.
• Partner programs are progressing well, with positive results reported for batoclimab and other therapies.
• The company's inclusion in the Nasdaq Biotechnology Index is a positive recognition of its market position.
• Cash provided by operating activities was $2.3 million for 2023.

Negatives

• Revenue decreased significantly in the fourth quarter and full year 2023 compared to 2022, primarily due to the absence of a large milestone payment.
• The company experienced a net loss of $14.1 million in the fourth quarter and $50.6 million for the full year 2023.
• Research and development expenses increased in both the fourth quarter and full year 2023.
• General and administrative expenses also increased for the full year 2023.

Risks

• The company's future success depends on the acceptance of its technology platform by partners.
• Biopharmaceutical development is inherently uncertain, and there are risks associated with the development, approval, and commercialization of partner products.
• Changes in technology and the competitive environment in the life sciences market pose risks.
• The company faces risks related to maintaining, protecting, and defending its intellectual property rights.
• Unstable market and economic conditions may have adverse consequences on the business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb expects operating expenses in 2024 to be approximately the same as in 2023 and anticipates cash use in 2025 to be substantially lower than in 2024 due to the progression of partnered programs. The company believes its current cash balance and cash from operations are sufficient to fund operations for the foreseeable future.

Management Comments

• Matt Foehr, Chief Executive Officer of OmniAb, stated that 2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs.
• Matt Foehr also noted that partners exceeded expectations regarding the number of new programs entering the clinic, with a total of six new entrants last year.
• Management believes they are now staffed and resourced to efficiently leverage the future growth of the business.

Industry Context

The announcement reflects the ongoing trends in the biotechnology industry, where companies are focused on developing innovative antibody-based therapeutics through partnerships and technology advancements. The progress of OmniAb's partner programs and the launch of new technologies align with the industry's emphasis on novel drug discovery and development.

Comparison to Industry Standards

• The decrease in revenue for OmniAb is largely attributed to the absence of a large milestone payment, which is not uncommon in the biotech industry where revenue can fluctuate based on the timing of such payments.
• The increase in R&D expenses is typical for a company investing in technology and clinical development, similar to other biotech companies like Regeneron or BioNTech.
• The number of new licenses and clinical programs initiated by OmniAb is comparable to other companies in the antibody discovery space, such as AbCellera or Ligand Pharmaceuticals.
• The positive clinical trial results reported by Immunovant for batoclimab are a significant milestone, similar to other successful antibody-based therapies in development by companies like Roche or AbbVie.
• The approval of sugemalimab in China is a notable achievement, comparable to other successful drug approvals in the oncology space by companies like Merck or Bristol Myers Squibb.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net loss, but encouraged by the progress in partner programs and technology launches.
• Employees may be impacted by the company's financial performance, but the company's growth plans may provide opportunities.
• Partners may be encouraged by the progress of their programs and the launch of new technologies.
• Customers may benefit from the development of new therapeutics through OmniAb's platform.

Next Steps

• OmniAb will continue to advance its partner programs and technologies.
• The company will focus on leveraging its resources to drive future growth.
• Immunovant's Phase 3 trials for batoclimab are expected to produce topline data in the second half of 2024 and the first half of 2025.
• Genmab plans to announce additional Phase 2 data for acasunlimab in the first half of 2024 and initiate a Phase 3 study in 2024.
• Arcus and Gilead will focus on advancing Phase 3 studies of domvanalimab + zimberelimab, with full enrollment expected by year-end 2024.

Key Dates

Keywords

OmniAb, Antibody Discovery, Biotechnology, Therapeutics, Clinical Trials, Partnerships, OmniDeep, OmnidAb, Financial Results, Milestone Payments